CYP2D6 polymorphisms and tamoxifen metabolism: Clinical relevance

Current Oncology Reports

Volumn 12, Issue 1, 2010, Pages 7-15

  Higgins, Michaela J ^a   Stearns, Vered ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

CYP2D6; Pharmacogenetics; Tamoxifen

Indexed keywords

CYTOCHROME P450 2D6; PAROXETINE; TAMOXIFEN;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOPROPHYLAXIS; DNA POLYMORPHISM; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME ACTIVITY; GENE FREQUENCY; GENE FUNCTION; GENETIC VARIABILITY; GENOTYPE; HOT FLUSH; HUMAN; NULL ALLELE; OVERALL SURVIVAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TAMOXIFEN;

EID: 76749143669     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0076-5     Document Type: Review

References (56)

1. A Jemal R Siegel E Ward, et al. 2009 Cancer statistics, 2009 CA Cancer J Clin 59 225 249 10.3322/caac.20006 19474385
2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
3. AE Guttmacher FS Collins 2003 Welcome to the genomic era N Engl J Med 349 996 998 10.1056/NEJMe038132 1:CAS:528:DC%2BD3sXntFeitrc%3D 12954750 (Pubitemid 37064775)
4. R Weinshilboum 2003 Inheritance and drug response N Engl J Med 348 529 537 10.1056/NEJMra020021 12571261 (Pubitemid 36159889)
5. WE Evans HL McLeod 2003 Pharmacogenomics-drug disposition, drug targets, and side effects N Engl J Med 348 538 549 10.1056/NEJMra020526 1:CAS:528:DC%2BD3sXovVKlsQ%3D%3D 12571262 (Pubitemid 36159890)
6. Z Desta BA Ward NV Soukhova DA Flockhart 2004 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6 J Pharmacol Exp Ther 310 1062 1075 10.1124/jpet.104.065607 1:CAS:528:DC%2BD2cXnt1eqtb0%3D 15159443 This article offers a thorough explanation of the metabolism pathway of tamoxifen outlining the contribution of CYP450 enzymes. (Pubitemid 39108928)
7. C Fabian L Tilzer L Sternson 1981 Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer Biopharm Drug Dispos 2 381 390 10.1002/bdd.2510020407 1:STN:280:DyaL38%2Fpt1ajsg%3D%3D 7317574
8. MD Johnson H Zuo KH Lee, et al. 2004 Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen Breast Cancer Res Treat. 85 151 159 10.1023/B:BREA.0000025406.31193.e8 1:CAS:528:DC%2BD2cXjsVertbc%3D 15111773 (Pubitemid 38987269)
9. YC Lim L Li Z Desta, et al. 2006 Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells J Pharmacol Exp Ther 318 503 512 10.1124/jpet.105.100511 1:CAS:528:DC%2BD28XnslOls7o%3D 16690721 (Pubitemid 44061223)
10. V Stearns MD Johnson JM Rae, et al. 2003 Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 95 1758 1764 1:CAS:528:DC%2BD3sXpvVelsbc%3D 14652237
11. X Wu JR Hawse M Subramaniam, et al. 2009 The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells Cancer Res 69 1722 1727 10.1158/0008-5472. CAN-08-3933 1:CAS:528:DC%2BD1MXisFSrtr8%3D 19244106
12. S Borges Z Desta L Li, et al. 2006 Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment Clin Pharmacol Ther 80 61 74 10.1016/j.clpt.2006.03.013 1:CAS:528:DC%2BD28Xms1enu7k%3D 16815318 (Pubitemid 43946844)
13. D Sun AK Sharma RW Dellinger, et al. 2007 Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases Drug Metab Dispos 35 2006 2014 10.1124/dmd.107.017145 1:CAS:528:DC%2BD2sXht1Cnu7vJ 17664247 (Pubitemid 350010805)
14. S Nowell C Sweeney M Winters, et al. 2002 Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy J Natl Cancer Inst 94 1635 1640 1:CAS:528:DC%2BD38XosFOgsbw%3D 12419790
15. SA Nowell J Ahn JM Rae, et al. 2005 Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients Breast Cancer Res Treat 91 249 258 10.1007/s10549-004-7751-x 1:CAS:528:DC%2BD2MXltFGqsLs%3D 15952058 (Pubitemid 40903087)
16. C Rodriguez-Antona M Ingelman-Sundberg 2006 Cytochrome P450 pharmacogenetics and cancer Oncogene 25 1679 1691 10.1038/sj.onc.1209377 1:CAS:528:DC%2BD28XisFyhtbY%3D 16550168
17. Home page of the Human cytochrome P450 (CYP) Allele Nomenclature. Edited by Ingelman-Sundberg M, Daly AK, Nebert DW. Available at http://www.cypalleles. ki.se. Accessed November 23, 2009.
18. LD Bradford 2002 CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants Pharmacogenomics 3 229 243 10.1517/14622416.3.2. 229 1:CAS:528:DC%2BD38XitlWqu70%3D 11972444 (Pubitemid 34223859)
19. S Garte L Gaspari AK Alexandrie, et al. 2001 Metabolic gene polymorphism frequencies in control populations Cancer Epidemiol Biomarkers Prev 10 1239 1248 1:CAS:528:DC%2BD38XnsFSjsg%3D%3D 11751440
20. M Ingelman-Sundberg 2005 Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity Pharmacogenomics J 5 6 13 10.1038/sj.tpj.6500285 1:CAS:528: DC%2BD2MXivFKntQ%3D%3D 15492763 (Pubitemid 40220611)
21. A Gaedigk LD Bradford KA Marcucci JS Leeder 2002 Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans Clin Pharmacol Ther 72 76 89 10.1067/mcp.2002.125783 1:CAS:528:DC%2BD38Xms1altrw%3D 12152006 (Pubitemid 34833189)
22. ML Dahl I Johansson L Bertilsson, et al. 1995 Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis J Pharmacol Exp Ther 274 516 520 1:CAS:528:DyaK2MXntVWlu7w%3D 7616439
23. CL Alfaro YW Lam J Simpson L Ereshefsky 2000 CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations J Clin Pharmacol 40 58 66 10.1177/00912700022008702 1:CAS:528:DC%2BD3cXivF2ksbs%3D 10631623
24. Y Jin Z Desta V Stearns, et al. 2005 CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 30 39 1:CAS:528:DC%2BD2MXisVaqsw%3D%3D 15632378
25. TP Ahern L Pedersen DP Cronin-Fenton, et al. 2009 No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications Cancer Epidemiol Biomarkers Prev 18 2562 2564 10.1158/1055-9965.EPI- 09-0516 1:CAS:528:DC%2BD1MXhtFWltb7N 19690182
26. RE Aubert EJ Stanek J Yao, et al. 2009 Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors [abstract] J Clin Oncol 28 508
27. VO Dezentje NJ Van Blijderveen H Gelderblom, et al. 2009 Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: a pharmacoepidemiologic study [abstract] J Clin Oncol 27 509
28. JN Ingle VJ Suman JA Mailliard, et al. 2006 Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52 Breast Cancer Res Treat 98 217 222 10.1007/s10549-005-9152-1 1:CAS:528:DC%2BD28XmvVarsr8%3D 16538529 (Pubitemid 44050772)
29. MP Goetz JM Rae VJ Suman, et al. 2005 Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes J Clin Oncol 23 9312 9318 10.1200/JCO.2005.03.3266 1:CAS:528: DC%2BD28Xnt1ynuw%3D%3D 16361630 This article offers the first retrospective study of the relationship between CYP2D64 status and clinical outcome in 256 women receiving adjuvant tamoxifen. Recurrence-free survival was significantly reduced among CYP2D64/4 patients relative to patients with wild-type genotype. (Pubitemid 46260189)
30. MP Goetz SK Knox VJ Suman, et al. 2007 The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen Breast Cancer Res Treat 101 113 121 10.1007/s10549-006-9428-0 1:CAS:528:DC%2BD2sXisVylsg%3D%3D 17115111 (Pubitemid 47555336)
31. P Wegman L Vainikka O Stal, et al. 2005 Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients Breast Cancer Res 7 R284 R290 10.1186/bcr993 1:CAS:528:DC%2BD2MXitF2qtr0%3D 15987423
32. P Wegman S Elingarami J Carstensen, et al. 2007 Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer Breast Cancer Res 9 R7 10.1186/bcr1640 17244352 (Pubitemid 350215154)
33. W Schroth L Antoniadou P Fritz, et al. 2007 Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes J Clin Oncol 25 5187 5193 10.1200/JCO.2007.12.2705 1:CAS:528:DC%2BD2sXhsVKnsbzN 18024866 (Pubitemid 350232249)
34. HS Lim H Ju Lee K Seok Lee, et al. 2007 Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer J Clin Oncol 25 3837 3845 10.1200/JCO.2007.11.4850 1:CAS:528:DC%2BD2sXhtFanu7zK 17761971 (Pubitemid 47477258)
35. K Kiyotani T Mushiroda M Sasa, et al. 2008 Impact of CYP2D6 10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy Cancer Sci 99 995 999 10.1111/j.1349-7006.2008.00780.x 1:CAS:528:DC%2BD1cXlslCrtrc%3D 18294285 (Pubitemid 351997603)
36. Y Xu Y Sun L Yao, et al. 2008 Association between CYP2D610 genotype and survival of breast cancer patients receiving tamoxifen treatment Ann Oncol 19 1423 1429 10.1093/annonc/mdn155 1:STN:280:DC%2BD1cvotVKmsA%3D%3D 18407954
37. Ramon YCT, Altes A, Pare L, et al.: Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat 2009 Feb 3 (Epub ahead of print).
38. W Schroth MP Goetz U Hamann, et al. 2009 Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen JAMA 302 1429 1436 10.1001/jama.2009.1420 1:CAS:528: DC%2BD1MXht1CksrjO 19809024 This article discusses a recent combined retrospective and prospective study of 1325 patients treated with tamoxifen in the adjuvant setting. The investigators reported a significantly reduced recurrence-free survival in intermediate or poor metabolizers of tamoxifen compared with extensive metabolizers.
39. Okishiro M, Taguchi T, Jin Kim S, et al.: Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 2009, 115:952-961.
40. MJ Bijl RH van Schaik LA Lammers, et al. 2009 The CYP2D6 4 polymorphism affects breast cancer survival in tamoxifen users Breast Cancer Res Treat 118 125 130 10.1007/s10549-008-0272-2 1:CAS:528:DC%2BD1MXht1GmtbbI 19189212
41. TL Lash EA Lien HT Sorensen S Hamilton-Dutoit 2009 Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 10 825 833 10.1016/S1470-2045(09)70030-0 1:CAS:528:DC%2BD1MXptlals7s%3D 19647203 This article provides commentary describing the controversy regarding the adoption of routine CYP2D6 testing in the clinic.
42. SA Narod JS Brunet P Ghadirian, et al. 2000 Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group Lancet 356 1876 1881 10.1016/S0140-6736(00)03258-X 1:CAS:528:DC%2BD3cXovFWjsL8%3D 11130383
43. J Gronwald N Tung WD Foulkes, et al. 2006 Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update Int J Cancer 118 2281 2284 10.1002/ijc.21536 1:CAS:528:DC%2BD28XjsVCgt7Y%3D 16331614
44. WG Newman KD Hadfield A Latif, et al. 2008 Impaired tamoxifen metabolism reduces survival in familial breast cancer patients Clin Cancer Res 14 5913 5918 10.1158/1078-0432.CCR-07-5235 1:CAS:528:DC%2BD1cXhtFaitrjF 18794105
45. Bonanni B, Macis D, Maisonneuve P, et al.: Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 2006, 24:3708-3709; author reply 3709.
46. Lynn Henry N, Rae JM, Li L, et al.: Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat 2009, 117:571-575.
47. JM Rae MJ Sikora NL Henry, et al. 2009 Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients Pharmacogenomics J 9 258 264 10.1038/tpj.2009.14 1:CAS:528:DC%2BD1MXlsVKksbw%3D 19421167
48. Y Jin DF Hayes L Li, et al. 2008 Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy J Clin Oncol 26 5849 5854 10.1200/JCO.2008.16.8377 19018086
49. QX Zhang A Borg DM Wolf, et al. 1997 An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer Cancer Res 57 1244 1249 1:CAS:528:DyaK2sXit1OjtrY%3D 9102207
50. M Baum AU Budzar J Cuzick, et al. 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2131 2139 10.1016/S0140-6736(02)09088-8 1:CAS:528:DC%2BD38XkslGhsLY%3D 12090977 (Pubitemid 34694019)
51. RC Coombes E Hall LJ Gibson, et al. 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081 1092 10.1056/NEJMoa040331 1:CAS:528:DC%2BD2cXitV2qtbc%3D 15014181 (Pubitemid 38298988)
52. B Thurlimann A Keshaviah AS Coates, et al. 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747 2757 10.1056/NEJMoa052258 16382061 (Pubitemid 43016814)
53. RS Punglia HJ Burstein EP Winer JC Weeks 2008 Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis J Natl Cancer Inst 100 642 648 10.1093/jnci/djn100 1:CAS:528:DC%2BD1cXlslymtbc%3D 18445827
54. CX Ma AA Adjei OE Salavaggione, et al. 2005 Human aromatase: gene resequencing and functional genomics Cancer Res 65 11071 11082 10.1158/0008-5472.CAN-05-1218 1:CAS:528:DC%2BD2MXht1Kjsr3F 16322257 (Pubitemid 41713378)
55. R Colomer M Monzo I Tusquets, et al. 2008 A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma Clin Cancer Res 14 811 816 10.1158/1078-0432.CCR-07-1923 1:CAS:528:DC%2BD1cXhsFykt7g%3D 18245543 (Pubitemid 351231164)
56. R Connolly V Stearns 2009 The role of pharmacogenetics in selection of breast cancer treatment Current Breast Cancer Reports 1 190 197 10.1007/s12609-009-0027-z 1:CAS:528:DC%2BD1MXhsVynurnN